Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015

BLINCYTO, Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in US and EU, Shows Benefit in Phase 2 Trial in Patients With Persistent or Recurrent Minimal Residual Disease (MRD)Data Show Positive Outcomes in Difficult-to-Treat Patient Subpopulations

Amgen - Investors - RSS Content